Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foresee Pharmaceuticals CoROCO:6576 -2.08%62 PS Ratio is 28.64 as of Jul. 19, 2026, which is 53% below its 10-year median of 61.44. GuruFocus rates ROCO:6576 with a GF Score™ of 62/100 and a GF Value™ of NT$96.76 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, Foresee Pharmaceuticals Co ranks worse than 95.28% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Foresee Pharmaceuticals Co's share price is NT$79.90.
Foresee Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.79. Hence, Foresee Pharmaceuticals Co's PS Ratio for today is 28.64.
Warning Sign:
Foresee Pharmaceuticals Co Ltd stock PS Ratio (=28.7) is close to 1-year high of 31.18.
The historical rank and industry rank for Foresee Pharmaceuticals Co's PS Ratio or its related term are showing as below:
ROCO:6576'
s PS Ratio Range Over the Past 10 Years
Min: 19.71 Med: 61.44 Max: 2038.57
Current: 28.64
During the past 12 years, Foresee Pharmaceuticals Co's highest PS Ratio was 2038.57. The lowest was 19.71. And the median was 61.44.
ROCO:6576's PS Ratio is ranked worse than 95.28% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs ROCO:6576: 28.64
During the past 12 years, Foresee Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 98.10% per year. The lowest was -12.00% per year. And the median was 32.90% per year.
Back to Basics: PS Ratio
Foresee Pharmaceuticals Co (ROCO:6576) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Foresee Pharmaceuticals Co PS Ratio Related Terms
Foresee Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Foresee Pharmaceuticals Co's Share Price of today is NT$79.90. Foresee Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Foresee Pharmaceuticals Co (ROCO:6576) has a PS Ratio of 28.64 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Foresee Pharmaceuticals Co and its competitors. This is 53% below median its historical median of 61.44. Over the past decade, Foresee Pharmaceuticals Co's PS Ratio has ranged from 19.71 to 2,038.57. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #909 out of 954 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is Foresee Pharmaceuticals Co's PS Ratio too high?
Foresee Pharmaceuticals Co's current PS Ratio of 28.64 is 53% below median its 10-year median of 61.44. Over the past 10 years, this metric has ranged from a low of 19.71 to a high of 2,038.57. The Drug Manufacturers industry median PS Ratio is 2.32. Foresee Pharmaceuticals Co's value of 28.64 is 1134.5% above this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #909 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #909 out of 954 companies for PS Ratio. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 2.32. Foresee Pharmaceuticals Co's value of 28.64 is 1134.5% above this benchmark. Historically, Foresee Pharmaceuticals Co's own PS Ratio has ranged from 19.71 to 2,038.57 over the past decade. While the company's 10-year median is 61.44 vs. the industry median of 2.32, Foresee Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current PS Ratio of 28.64 is 1134.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Foresee Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current PS Ratio is 28.64, which is 53% below median its own 10-year median of 61.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.76, compared to a current price of NT$79.90 — trading 17.4% below its estimated fair value. The current PS Ratio is 28.64, which is 53% below median its 10-year median of 61.44 and 1134.5% above the Drug Manufacturers industry median of 2.32. Foresee Pharmaceuticals Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current PS Ratio is 28.64 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$79.90 is trading 17.4% below its estimated GF Value™ of NT$96.76.
GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for ROCO:6576:
PS Ratio: 28.64 (53% below median its 10-year median of 61.44)
GF Value™: NT$96.76 vs. price of NT$79.90 (17.4% below fair value)
Industry Position: 1134.5% above the Drug Manufacturers median (#909 of 954)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
62GF Score
Get the complete analysis for ROCO:6576
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
